Klimik Journal is a pivotal publication in the fields of Infectious Diseases and Medical Microbiology, serving as a platform for researchers, clinicians, and academics to disseminate groundbreaking findings and improve health outcomes. Established in 2010 and published by DOC DESIGN INFORMATICS CO LTD, this journal is dedicated to advancing knowledge and fostering discussions around critical issues in infectious diseases and microbial research. With an ISSN of 1301-143X and an E-ISSN of 1309-1484, Klimik Journal strives to maintain high academic standards despite currently ranking in the fourth quartile in both categories according to Scopus metrics, which highlights the need for continued contributions to the field. Operating from Turkey, the journal is committed to supporting open access options, thereby ensuring wide dissemination of research findings. As it continues to bridge the gap between theory and practice, Klimik Journal is poised to become an essential resource for those looking to stay at the forefront of infectious disease research and microbiological advancements.

The Brazilian Journal of Infectious Diseases, published by Elsevier Brazil, is a premier open-access journal dedicated to advancing research and clinical practice in the field of infectious diseases. Since its inception in 2001, this journal has been pivotal in disseminating innovative studies and reviews that inform healthcare professionals and researchers alike. With an impressive impact factor reflected by its ranking in the second quartile for Infectious Diseases and third quartile for Medical Microbiology in 2023, the journal ranks #127 out of 344 in medicine – infectious diseases and #61 out of 140 in medical microbiology, showcasing its reputable standing in the scientific community. The Brazilian Journal of Infectious Diseases invites contributions that highlight significant findings, novel methodologies, and critical reviews aimed at enhancing patient care and public health initiatives. With an international readership and a focus on pressing issues in infectious diseases, it serves as an essential platform for knowledge exchange and collaboration among scholars and practitioners across Brazil and beyond. By reinforcing the importance of open access to scientific literature, this journal not only promotes transparency but also enhances the global discourse surrounding infectious diseases.

BMC Infectious Diseases is a premier open-access journal published by BMC in the United Kingdom, dedicated to the field of infectious diseases. Established in 2001, this journal has been at the forefront of disseminating high-quality, peer-reviewed research, contributing significantly to the global understanding of infectious pathogens and their impact on public health. With a 2023 Scopus ranking of #100 out of 344 in the Medicine - Infectious Diseases category, and a notable Q1 quartile classification, it stands as a vital resource for researchers and professionals alike. Authors benefit from the journal's broad reach and visibility, ensuring their work is accessible to a wide audience. Access options are fully open, allowing for seamless dissemination of knowledge in the ongoing battle against infectious diseases. With an established history of publishing groundbreaking studies, BMC Infectious Diseases plays a crucial role in addressing critical issues and advancing research in the ever-evolving landscape of infectious diseases.

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, published by W B SAUNDERS CO-ELSEVIER INC, stands as a premier academic resource in the field of infectious diseases and microbiology. With its ISSN 0891-5520 and E-ISSN 1557-9824, this esteemed journal has been at the forefront of disseminating critical research findings and clinical advancements since its inception in 1987. Known for its high impact, the journal ranks in the Q1 category for both Infectious Diseases and Medical Microbiology as of 2023, which underscores its significant contribution to advancing knowledge and practice in these vital areas. Researchers, practitioners, and students alike rely on its comprehensive yet concise reviews and original articles, ensuring they stay abreast of emerging trends and therapeutics in infectious disease management. Although it does not offer open access, the journal remains pivotal in enriching scholarly dialogue and influencing clinical practices in the United States and beyond. Explore this vital publication and join a community dedicated to excellence in infectious disease research.

JOURNAL OF INFECTION AND CHEMOTHERAPY, published by Elsevier, is a leading journal in the fields of Infectious Diseases, Microbiology, and Pharmacology. With a solid reputation reflected in its prestigious Q2 ranking in Infectious Diseases and Pharmacology, and Q3 in Microbiology (medical), this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements in the diagnosis, treatment, and prevention of infectious diseases. The journal provides a platform for high-quality, peer-reviewed scholarly articles, making it an essential reference point in the medical community. Despite being published without open access, it continues to attract significant scholarly attention, as denoted by its rankings in Scopus, which showcases its impact within the academic landscape. With a timeline converging from 1995 to 2024, JOURNAL OF INFECTION AND CHEMOTHERAPY is dedicated to advancing knowledge and contributing to better health outcomes globally.

INFECTIOUS DISEASES IN CLINICAL PRACTICE, published by Lippincott Williams & Wilkins, is a crucial resource in the field of infectious diseases and microbiology. With an ISSN of 1056-9103 and an E-ISSN of 1536-9943, this journal has been a platform for scholarly communication since its inception in 1992, now spanning over two decades of continuous publication. The journal primarily focuses on the latest research developments, case studies, and clinical practices relevant to infectious diseases, making it an indispensable tool for researchers, healthcare professionals, and students alike. Although it is currently categorized in the Q4 quartile for both Infectious Diseases and Medical Microbiology, it continues to strive for excellence and relevance in a rapidly evolving field. By facilitating open access to impactful articles (note: Open Access not applicable), the journal aims to enhance global understanding and management of infectious diseases, ensuring that practitioners are well-equipped to confront contemporary challenges in this critical area of public health. Situated in the United States at TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103, INFECTIOUS DISEASES IN CLINICAL PRACTICE plays an essential role in fostering academic discourse and advancing clinical knowledge.

Revista de Epidemiologia e Controle de Infeccao, published by Universidade de Santa Cruz do Sul, stands as a vital resource for scholars and practitioners in the fields of epidemiology and infection control. This open-access journal, available since 2011, fosters the dissemination of high-quality research and practice-based knowledge aimed at enhancing public health and improving infection management strategies. With its commitment to sharing invaluable insights from Brazil and beyond, the journal encourages broader participation in critical discussions surrounding infectious diseases. Although specific metrics such as the HIndex and Scopus rankings are currently omitted, the journal's relevance is underscored by its open accessibility, allowing a global audience of researchers, healthcare professionals, and students to engage with innovative studies and findings in this essential area of public health.

International Journal of Antimicrobial Agents, published by Elsevier, stands as a premier platform in the fields of Infectious Diseases, Microbiology, and Medical Pharmacology. With an impressive impact factor and ranked in the Q1 category across multiple medical disciplines in 2023, this journal is recognized for its contribution to advancing knowledge and understanding in the efficacy and safety of antimicrobial treatments. Its comprehensive scope from 1991 to 2024 allows for the publishing of original research, reviews, and commentary on pressing issues related to antimicrobial resistance, treatment strategies, and pharmacological innovations. With a strong emphasis on high-quality research as reflected in its Scopus rankings, the journal is an essential resource for researchers, clinicians, and students dedicated to improving patient outcomes in the face of evolving microbiological challenges. Engage with the latest findings and methodologies through this vital academic resource, available in print and online, from the heart of the Netherlands.

Infection and Chemotherapy, an esteemed journal published by the Korean Society of Antimicrobial Therapy, focuses on the dynamic fields of infectious diseases and pharmacology. With an ISSN of 2093-2340 and an E-ISSN of 2092-6448, this peer-reviewed, open-access journal has been providing a crucial platform for research dissemination since 2008. Based in South Korea, it boasts a significant impact in the academic community, as evidenced by its Q2 ranking in both Infectious Diseases and Pharmacology categories for 2023. It holds a Scopus rank of 64 out of 272 in Pharmacology and 98 out of 344 in Infectious Diseases, showcasing its prominence and the quality of research it publishes. With a focus on advancing scientific knowledge, Infection and Chemotherapy is committed to fostering essential dialogues among researchers, clinicians, and students, making it a vital resource for those engaged in the fight against infectious diseases and the development of effective therapeutic protocols.

New Microbes and New Infections is an esteemed peer-reviewed journal published by Elsevier Sci Ltd that has been a prominent platform for disseminating groundbreaking research in the fields of Infectious Diseases and Microbiology since its establishment in 2013. With an impressive Open Access model, this journal ensures that vital research findings are readily accessible to researchers, healthcare professionals, and academics worldwide. Positioned in the Q2 category for Infectious Diseases and Q3 for Microbiology in 2023, it reaches a significant global audience, as demonstrated by its high Scopus rankings—#44 out of 344 in Medicine: Infectious Diseases, and #34 out of 182 in Immunology and Microbiology. The journal aims to inspire new ideas and foster collaborations by publishing high-quality research focused on novel microbes and infections, thus playing a crucial role in advancing science and public health in an era where understanding infectious agents is more vital than ever.